Factors regulating Hb F synthesis in thalassemic diseases by Mastropietro, Fabrizio et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Blood Disorders
BMC Blood Disorders  2002,  2 x Research article
Factors regulating Hb F synthesis in thalassemic diseases
Fabrizio Mastropietro1, Guido Modiano2, Maria Pia Cappabianca1, 
Enrica Foglietta1, Carmelo D'Asero3, Mauro Mezzabotta1, 
Donatella Ponzini1, Laura Maffei1, Antonio Amato1, Maria Lerone1, 
Paola Grisanti1, Paola Di Biagio1, Silvana Rinaldi1 and Ida Bianco*1
Address: 1Associazione Nazionale per la lotta contro Ie Microcitemie in Italia, Rome, Italy, 2Dipartimento di Biologia, Università Tor Vergata, 
Rome, Italy and 3Ospedale San Pietro-Fatebenefratelli, Rome, Italy
E-mail: Fabrizio Mastropietro - fazeman@tin.it; Guido Modiano - modiano@bio.uniroma2.it.it; Maria Cappabianca - kbianca16@libero.it; 
Enrica Foglietta - enrica.foglietta@inwind.it; Carmelo D'Asero - rmlabana@melograno.it; Mauro Mezzabotta - mezzabottamauro@virigilio.it; 
Donatella Ponzini - gchibb@tin.it; Laura Maffei - lauramaffei@tiscali.it; Antonio Amato - antamato@tiscalinet.it; 
Maria Lerone - marchioma@tiscalinet.it; Paola Grisanti - paolagrisanti@hotmail.com; Paola Di Biagio - paoladibiagio@hotmail.com; 
Silvana Rinaldi - simonarinaldi@tiscalinet.it; Ida Bianco* - ibianco@tin.it
*Corresponding author
Abstract
Background: The thalassemic syndromes originate from mutations of the globin genes that cause,
besides the characteristic clinical picture, also an increased Hb F amount. It is not yet clear if there are
more factors, besides the beta globin genotype, determining the Hb F production. We have tried to find
out if there are relations between total Hb and Hb F, between erythropoietin (Epo) and Hb F, between
Hb F and point mutations of the gamma gene promoters.
Materials and Methods: Hematologic parameters, iron status, alpha/non-alpha globin ratio, Epo level,
and thalassemic defects of the alpha-, beta-, and gamma-globin genes were explored using standard
methods in patients affected by thalassemic diseases. Ninety-five non thalassemic individuals have been
examined as controls.
Results: Two clinical variants of beta-thalassemia intermedia referred to as beta-thal int sub-silent and
evident are associated with distinct sets of mutations of the beta-globin gene. Silent beta thal mutations
are invariably associated with sub-silent beta thal int; beta° or severe beta+ thal mutations are associated
with evident beta thal int (88%) and almost invariably (98%) with thalassemia major. A positive correlation
was observed between the severity of the disease and the Hb F level, but no correlation was found
between the Hb F and erythropoietin (Epo) level. The mutation Ggamma -158 C→ T was detected in
26.9% of patients affected by beta-thal int sub-silent and evident, respectively, but only in 2% of patients
with thalassemia major.
Conclusions: The severity of beta-thal int and the increased Hb F level are strictly dependent from the
type of beta-globin gene mutations. No relation is found between Hb F synthesis and Epo secretion. The
mutation Ggamma -158 C→ T, common among patients affected by beta-thal int and very rare in thal major
patients, does not seem, in this study, to influence the Hb F content in beta thal int patients.
Background
The beta-thalassemia syndromes (thalassemia major and
beta-thalassemia intermedia) originate from the absence
of or from a reduction in the synthesis of structurally nor-
Published: 6 February 2002
BMC Blood Disorders 2002, 2:2
Received: 11 September 2001
Accepted: 6 February 2002
This article is available from: http://www.biomedcentral.com/1471-2326/2/2
© 2002 Mastropietro et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, 
provided this notice is preserved along with the article's original URL.BMC Blood Disorders 2002, 2 http://www.biomedcentral.com/1471-2326/2/2
Page 2 of 7
(page number not for citation purposes)
mal beta-globin chains. The beta-globin chain deficiency
contributes to the pathogenesis of anemia by impairing
the formation of functional Hb A and by causing ineffec-
tive erythropoiesis. The anemia stimulates the secretion of
Epo and leads to erythroid hyperplasia of the bone mar-
row and to an accelerated erythropoiesis [1]. As a result,
erythroblasts expressing the fetal globin gene are generat-
ed and fetal hemoglobin (Hb F) is synthesized in the post-
natal life [2]. Two more factors, the amplification of the
cellular clones producing F-cells and the slower turnover
of these cells in circulating blood favour the Hb F presence
in thalassemia [3]. In these affections the persistent syn-
thesis of Hb F is very important because it restores the al-
pha/non-alpha globin ratio, thus reducing the bone
marrow hyperplasia and ineffective erythropoiesis and
therefore the severity of disease.
Genetically, the beta-thalassemia syndromes are heteroge-
neous. The severity of these disorders is determined pri-
marily by the type of the gene defect as well as the gene
dosage.
The molecular analysis has uncovered that different clini-
cal variants of beta-thalassemia are associated with a wide
spectrum of different mutations of the beta-globin gene;
thalassemia major patients, characterized by a severe
transfusion-dependent anemia and a marked increase in
the synthesis of Hb F, are either homozygous carriers of
mutations that abolish the beta-globin synthesis (beta°
thai) or compound heterozygotes for beta° thal and severe
beta+ thal defects which drastically reduce it. These muta-
tions are referred to as severe beta-thal mutations. beta-
thal int patients which have a less severe anemia and a
modest increase in the synthesis of Hb F, are carriers
mainly of beta+ thal mutations that reduce slightly beta-
globin synthesis. These mutations are referred to as mild
beta-thal mutations.
Furthermore, deletions of the non-alpha globin gene clus-
ter encompassing the beta- and delta-globin genes are as-
sociated with a genetic variant of beta-thalassemia
(deltabeta thal), which is characterized by a marked in-
crease in the synthesis of Hb F even in the heterozygous
state. In these patients the gamma-globin genes remain in-
tact and are expressed in the postnatal life, thus reducing
the ineffective erythropoiesis and ameliorating the severi-
ty of the disease.
It is worth noting that also genetic factors unlinked to the
beta globin cluster, favour the Hb F synthesis in the post-
fetal life [4]. Particularly interesting for its frequency is the
polimorphic single-base substitution C→ T at Ggamma -
158, recognizable for the creation of a XmnI restriction
site, that appears to cause an increase of Hb F expecially
during erythropoietic stress.
Recently, it has been suggested that the increased synthe-
sis of Hb F associated with beta-thalassemia syndromes is
directly or indirectly dependent from the Epo level [5,6].
The aim of this study was to investigate the relationships
between the genetic defects and the severity of the disease
in patients affected by a thalassemic disease. In particular,
the relationships between the genetic defect, the total Hb,
and between the synthesis of Hb F and the Epo level have
been examined in patients with beta thalassemia interme-
dia (beta thal int). In addition, the distribution and fre-
quency of point mutations of the promoter region of
gamma-globin genes were analysed and the relationship
between these mutations and the content of Hb F was in-
vestigated. The analysis of the beta-globin gene and gam-
ma-globin gene mutations was extended also to patients
affected by Cooley's disease.
Subjects
Seventy-four patients with clinical picture of beta thal int
have been examined: 33 of them were affected by a mild
or sub-silent form of the disease, and 41 by an evident
clinical picture (Tab. 1). In addition, 58 patients carried a
beta thal defect and also a triplicated or quadruplicated al-
pha locus. Twenty-four patients were affected by tha-
lassemia major, and 15 by Hb H disease. The control
group included 53 healthy individuals and 42 iron-defi-
cient, non thalassemic patients.
Patients with an homozygotic condition for a delta beta
thal deletion were excluded from this study, since only Hb
F is synthesized. The patients homozygotes for severe
beta-globin defects, and carriers of an alpha thal defect,
were also excluded.
All of the individuals examined in this study were in the
post-puberal age.
Methods
Blood samples were collected in EDTA. Hematologic pa-
rameters were determined using a Technicon H1 Analyser
(Bayer). Hb A2, Hb F and Hb H values were determined
using an electrophoretic method [7]. Concentrations of
Hb F higher than normal were confirmed by radial immu-
nodiffusion (Quick Plate kit, Helena Laboratories, Beau-
mont, TX, USA). Serum iron and ferritin levels were
measured by standard methods. The serum level of eryth-
ropoietin (Epo) was determined using the Epo-Trac kit
(INSTAR Corporation, Stillwater, MN, USA). The average
value of 53 healthy individuals was assumed as the nor-
mal Epo concentration. Reticulocyte counts were per-
formed on fresh blood preparations stained with brilliant-
cresyl-blue. The synthesis of globin chains in vitro was de-
termined following the method of Clegg [8], using a high
pressure liquid chromatograph.BMC Blood Disorders 2002, 2 http://www.biomedcentral.com/1471-2326/2/2
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The Amplification Refractory Mutation System (ARMS)
was used to detect mutations of the beta- and gamma-
globin genes [9,10] and a modified PCR method previ-
ously described in our laboratories [11], was used to de-
tect alpha-globin genes defects. The patients affected by
thalassemia major or intermedia were screened for all of
the beta- and alpha-globin gene mutations present in the
Italian population (Tab. 4, ref. [4,12]) and the mutations
analysis was also extended to mutations of the promoter
region of the gamma-globin genes which are until report-
ed to occur in the Italian population (Ggamma-158 C→ T;
Agamma -196 C→ T; Ggamma -175 T→ C; Agamma -117
G→ A; AgammaT and the deletion Agamma -225/-222
bp). The Ggamma -158 C→ T and AgammaT substitutions
were searched in all of the subjects reported in Table 1.
The remaining mutations of the gamma genes promoters
were searched in 286 more chromosomes of beta-tha-
lassemia patients or control subjects.
The statistical significance was evaluated using the Stu-
dent's t-test. Linear regressions were fitted by the least
square deviations method and the correlation coefficient
r was calculated according to a standard formula. A p val-
ue < 0.05 was assumed to be statistically significant, as
only few tests were performed.
Results
The analysis of the hematologic data and the clinical
symptoms of 74 patients affected by beta-thal int indicate
that this disease can be classified into two clinical variants
referred to as sub-silent and evident beta-thal int (Table
1). The patients with sub-silent beta-thal int have a re-
duced total Hb content and show no or very mild clinical
symptoms. The patients with evident beta-thal int show
severe clinical symptoms, often associated with massive
splenomegaly, and 41% of them have undergone splenec-
tomy. The Hb content is significantly lower than that of
the patient with sub-silent beta-thal int (t = 7.44; gl 72; p
< 0.001). The Hb F level is higher in with evident than in
patients with sub-silent beta-thal int, and the difference is
statistically significant (t = 2.28; gl 72; p < 0.05). Thus, the
severity of clinical symptoms of beta-thal int correlates
with a decrease of the total Hb content and an increase of
the Hb F content. Normally the Hb F content is positively
correlated with the total Hb content, as illustrated in Fig 2.
In the 42 iron-deficient but not thalassemic subjects, the
Epo level ranging from 2.7 to 1960 mU/1 with a mean val-
ue of 160.10 ± 312.60 mU/1, was negatively correlated (r
= -0.74) to the Hb content (Fig. 1). The correlation is sta-
tistically significant (n = 42; p < 0.001).
The mean Epo level of beta-thal int patients is apparently
lower than that of iron-deficient patients (Tab. 1). Regard-
ing to total Hb, only between the groups of sub-silent
beta-thal int patients and iron-deficient patients the dif-
ference is statistically significant (t = 2.17; gl 73; p < 0.05).
The mean values of the Epo level and the Hb F content in
the two groups of beta-thal int seem to be positively relat-
ed, but an accurate analysis of single cases indicates (Tab.
2) that the Epo level and Hb F content are unrelated: sub-
jects showing a low content of Hb F and an high level of
Epo as well as subjects showing an high content of Hb F
and a low level of Epo were frequently observed. This ob-
servation is reinforced by the analysis of groups of subjects
in which the severity of anemia is similar. Within the
group of evident beta tal int patients (the only adapt for
this analysis) subjects showing an Hb F level higher or
lower than 40% [5,6] were selected. As illustrated in Fig. 2
and Tab. 3, subjects having a very similar Epo level and
Table 1: Hematologic and hemoglobinic data and Epo levels in thalassemic patients and control subjects.
Group of patients N. cases Hb g/dl Hb F % EPO mU/l Glob. synth.
alpha non-alpha
Ret.
‰
Sub-silent beta thal int 33 10.1 ± 1.0 20.5 ± 18.2 3.0 →  .70.6 41.22 ± 32.00 11.66 →  136.6 2.10 31
Evident beta thal int 41 8.3 ± 1.16 33.40 ± 28.04 6.80 →  85.0 95.83 ± 64.33 17.84 →  218.97 2.20 60
beta thal int in double
heterozygous beta tha
 + triplicated alpha
58 10.0 ± 1.38 5.15 ± 3.9 2.0 →  19.3 28.45 ± 17.11* 7.85 →  60.72 2.50 30
Hb H disease 15 9.4 ± 1.2 < 1 32.88 ± 12.11** 0.52 28
Thal major 24 10.4 ± 1.0 7.7 ± 8.5*** 1.60 →  40.9 46.83 ± 40.78 9.82 →  129.59 17
Healthy non-thal subjects 53 14.4 ± 1.1 <1 11.90 ± 3.3 ~1.0 3
Iron-deficient non-thal subjects 42 8.7 ± 1.2 <1 160.10 ± 312.6 2.7 →  1960.0 8
* The measurement of Epo has been detected only in 17 patients. ** The measurement of Epo has been detected only in 10 patients. *** This value 
is not informative as patients were routinely transfused.BMC Blood Disorders 2002, 2 http://www.biomedcentral.com/1471-2326/2/2
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Hb content fall in both classes of Hb F content, indicating
that Hb F content and Epo level are not related.
Different sets of mutations of the globin genes are associ-
ated with groups of patients characterized by a different
severity of the disorder. The spectrum of the beta-globin
gene mutations commonly found in the Italian popula-
tion can be divided in three categories, the first of which
includes the -101 C→ T, -92 C→ T, and IVS II 844 C→ G
single nucleotide substitutions; the second the -87 C→ G,
-86 C→ G or C→ A, and IVS I C→ T single nucleotide sub-
stitutions, and the third the beta° 39 C → T, IVS I 110
G→ A, IVS II 745 C→ G single nucleotide substitutions and
the frameshift 6 (-A) mutation. These three categories are
referred to as silent beta-thal, mild beta-thal, and severe
beta-thal mutations, respectively.
In the group of 33 patients with sub-silent beta-thal int
the frequencies of silent beta-thal, mild beta-thal, and se-
vere beta-thal mutations were 37%, 13% and 50%, respec-
tively (Tab. 4). In the group of 42 patients with evident
beta-thal int, the most common and equally frequent
(44%) beta-globin gene defects were mild and severe
beta-thal mutations. The frequency of silent beta-thal mu-
tations was 12%. Conversely, severe beta-thal mutations
were found at high frequency (83%) in thalassemia major
patients. Silent beta-thal mutations were detected only in
a small fraction (2.1%) of thalassemia major patients.
In the 58 patients both heterozygous for a mutation of the
beta-globin gene and heterozygous or rarely homozygous
for the presence of three or four copies of one alpha-glob-
in locus, the beta-globin gene defects were invariably be-
ta° or severe beta+ thal mutations (Tab. 4 and ref. [13]);
the alpha-globin gene mutation was in 54 out of 58 pa-
tients a triplicated alpha anti 3.7 I gene cluster; in 3 pa-
tients a quadruplicated alpha anti 4.2 gene cluster, and in
one patient the homozygous condition for a triplicated al-
pha anti 3.7 I gene cluster. In these patients, the average
Hb content was 10.0 ± 1.38 g/dl (Table 1), the content of
Hb F was slightly higher than normal, ranging from 2.0 to
19.3 with an mean value of 5.15 ± 3.9 %, and the average
Epo level was 28.45 mU/1, ranging from 7.85 to 60.72
mU/l. This value is lower than that of regularly transfused
thalassemia major patients. Although the Hb F content
appears to be low in all these patients, their clinical pic-
ture is highly heterogeneous, 50% of the patients having a
sub-silent beta thal int, 30% an evident beta thal int and
20% a severe anemia with 5 transfusion dependent pa-
tients. Ten out of 58 patients (17.2%) have undergone
splenectomy.
The patients with Hb H disease have a normal Hb F level,
and a Epo level lower than that of patients with beta-thal
int.
In the beta-thalassemia patients and in the control sub-
jects, screened for the six mutations of the promoter re-
gion of the gamma-globin gene observed in Italy, only the
Ggamma -158 C→ T and AgammaT single nucleotide sub-
stitutions were detected. In all cases except 7 the Agam-
maT mutation was to the Agamma -225–222 bp deletion.
The frequencies of the Ggamma -158 C→ T and AgammaT
mutations are significantly different in the various groups
of beta-thalassemia patients (Tab. 5), with the lowest fre-
quency of the Ggamma -158 C→ T mutation (2.1%) in
thalassemia major patients.
In the group of patients with evident beta-thal int the fre-
quency of the Ggamma -158 C→ T mutation was 6.2% in
7 patients having a total Hb content > 9 g/dl and 1.6% in
32 patients having a total Hb content ≤  9 g/dl.
Discussion
It is well known that the severity of thalassemic diseases
(thalassemia major and thal int) syndromes is primarily
determined by the nature and type of mutations as well as
gene dosage of the globin genes underlying these disor-
ders. The results reported in this study extend this conclu-
sion to two clinical variants of beta-thal int, referred to as
sub-silent and evident beta-thal int. Distinct sets of muta-
tions of the beta-globin gene have been found associated
with these two variants of beta-thal int. Silent mutations
of the beta-globin gene were detected at high frequency in
patients affected by sub-silent beta-thal int, whereas mild
and severe mutations of the beta-globin gene were the
most common mutations amongst the patients affected
by evident beta-thal int (Table 4). This notion is rein-
forced by the high frequency (83%) of severe beta+ and
beta° mutations in patients affected by thalassemia major.
Several hematologic parameters of beta-thalassemia re-
flect the diversity of mutations at beta-globin locus. The
total Hb content was found to be significantly different
between patients affected by thalassemia major and pa-
Table 2: Total Hb, Hb F, and Epo level in patients with evident 
beta thal int.
Case Hb g/dl Hb F % EPO mU/l
11 0 . 5 8 7 2 3
41 0 . 6 7 0 5 5
11 7.2 21 132
19 8.2 7 51
20 7.4 24 126
21 9.0 12 233BMC Blood Disorders 2002, 2 http://www.biomedcentral.com/1471-2326/2/2
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tients with beta thal int, as well as between patients affect-
ed by sub-silent and patients with evident beta-thal int
(Table 1). These last two groups of patients showed also
significant differences in the content of Hb F (t = 2.28; df
= 72; p < 0.05).
The comparative analysis of the serum Epo level in groups
of patients affected by thalassemia diseases or iron defi-
ciency shows first of all that the synthesis of Epo, as pre-
dicted, is always directly related to the severity of anemia
and, consequently, inversely related to the total Hb con-
tent. Furthermore, in the thalassemic diseases mean Epo
level is consistently lower than that of iron deficient pa-
tients, probably as a result of the different pathophysiolo-
gy of the anemia in the two conditions. No firm
relationship could be established between the Epo and
Hb F levels. The variations of these two parameters in each
patient with evident beta thal int appear to be erratic (Tab.
2); and in patients having a similar level of both total Hb
and Epo, the amount of Hb F is indifferently higher or
Table 3: Epo level and Hb F content in a group of evident beta thal int patients showing a similar degree of anemia and divided for Hb 
F < or > 40%.
Patients' group N. cases Hb F and EPO mean levels
Evident beta thal int with Hb ≤  9 g/dl 32 HbF = 13.6% EPO = 92.9 mU/l (25 cases) Hb F = 59.9% EPO = 118.8 mU/l (7 cases)
Table 4: Distribution of beta thal alleles in beta thal int and thal major patients.
Type of thalassemic disease N. cases n. of
identified alleles
Alleles beta
thal silent
Alleles beta+
thal mild
Alleles beta+ thal
severe and beta ° thal
Sub-silent thal int 33 61 22 (37%) 8 (13%) 31 (50%)
Evident thal int 41 81 9 (12%) 36 (44%) 36 (44%)
beta thal int in double heterozygous beta 
thal + triplicated alpha
58 100 0 0 100 (100%)
Thal major 24 47 1 (2.1%) 7 (15%) 39 (83%)
The silent, mild, severe beta-thal defects present in Italy are: 1. Silent: -101 C→ T; -92 C→ T; IVS II-844 C→ G; triplicated alphaanti 3.7; triplicated 
alphaanti 4.2: ; they have a hematologic-hemoglobinic picture completely normal or with some mild thal characters. 2. mild or sub-silent: -87 C→ G or 
C→ T; -86 C→ G or C→ A; IVS-1 6 T→ C that have a constant but very mild thal hematologic picture and a mild increase of Hb A2. 3. severe: 
beta°39 C→ T; IVS 1–110 G→ A; IVS II-745 C→ G; frameshift 6 (-A) that have all very marked hematologic and hemoglobinic characters.
Table 5: Distribution of the Ggamma -158 C→ T and AgammaT mutations in thalassemic patients and in control subjects.
GROUP OF PATIENTS Allele frequencies
Ggamma-158 C→ T AgammaT
Sub-silent beta tal int 8.6 27.3
Evident beta tal int 18.3 26.6
beta tal int with genotype triplicated alpha + beta tal 16.6 17.6
Hb H disease 37.5 5.5
Tal major 2.1 35.4
Normal controls 25.0 18.0BMC Blood Disorders 2002, 2 http://www.biomedcentral.com/1471-2326/2/2
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lower than 40% (Tab. 3). Therefore, the data do not sup-
port the hypothesis that Hb F content is regulated by the
serum level ofEpo. The relationship between total Hb
content, Hb F content and Epo level were not studied in
patients with Hb H disease, since Hb F is in these patients
below the detection limit.
In patients with a compound heterozygosity for a triplicat-
ed copy of a alpha globin gene cluster and a beta globin
gene mutation, only a moderate increase of the Hb F level
(mean 5.5 ± 3.9% within a range from 2.0 to 19.3%) was
observed. This observation indicates that the excess of al-
pha globin chains, as assessed by the unbalanced alpha/
non-alpha globin ratio (2.5) is not sufficient to increase
the gamma-globin chains synthesis.
Only the Ggamma -158 C→ T and AgammaT single nucle-
otide substitutions out of 6 gamma gene promoter region
mutations explored in this study were detected, and their
frequencies varied in different groups of patients (Table
5). The role of this mutation in determining the Hb F
amount is not yet definitively cleared. The demonstration,
already reported by other Authors [14], that the frequency
of Ggamma -158 mutation is very low in beta thal major
patients (Tab. 5), and, inside the beta thal int patients,
higher in those with a higher amount of total Hb and low-
er in those with a lower amount of total Hb, seems to in-
dicate that this mutation is important in ameliorating the
severity of the disease.
Conversely, other obstervations [15–17] report that this
mutation does not influence the Hb F content of subjects
which are heterozygous for a beta thal mutation [16] as
well as of heterozygous compounds for a beta thal muta-
tion and a triplicated or quadruplicated copy of the alpha-
globin cluster.
At variance with these observations, in sickle cell disease
patients carrying some betas haplotypes which show a
high frequency (up to 100%) of the Ggamma -158 C→ T
mutation, show also an increase of the Hb F content that
leads to a reduction of the severity of the disease [18].
Figure 1
Negative correlation between total Hb content and Epo level
in iron-deficient patients. The logarithm of the Epo level plot-
ted against the corresponding total Hb content of each
patient is denoted by a blue square. The linear regression
(solid line) fitting the data is described by the following equa-
tion: log [Epo] = 4.78–0.33 [Hb]. The correlation coefficient
r is -0.74.
Figure 2
Epo level and Hb F content are not related in patients with β -
thalassemia intermedia. The logarithm of the Epo level was
plotted against the corresponding total Hb content of each
patient. The patients showing an increase of Hb F higher than
40% are represented by red squares, whereas the blue
squares denote the patients showing an increase of Hb F
equal to or less than 40%.BMC Blood Disorders 2002, 2 http://www.biomedcentral.com/1471-2326/2/2
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The relationship between the content of Hb F and point
mutations of the promoter region of the gamma-globin
genes in thalassemic patients needs then to be further in-
vestigated. The analysis must be extended to those muta-
tions of the gamma-globin gene promoter region that have
not yet been detected in the population of Italy or other
Mediterranean countries. The hypothesis [19] that the
Ggamma -158 C→ T mutation when linked in cis to the se-
quence motif (AT)x(T)y mapping at position -530 in the 5'
untranslated region of the beta-globin gene could interact
to generate a high expression of Hb F under the erythro-
poietic stress, has to be ulteriorly evaluated. Finally, the
role played by loci unlinked to the beta-globin locus in the
regulation of Hb F synthesis remains to be elucidated. Two
candidate regulatory loci have been mapped at Xp22 [FCP
locus [20,21]] and 6q22.3-23.2 [22].
A study regarding all these factors, obviously necessary
also for the various heterozygotic thalassemic conditions,
is now in progress in our laboratories.
Conclusions
The severity of beta-thalassemia syndromes including the
increased synthesis of Hb F is primarily determined by the
genotype of the beta-globin locus. The synthesis of Hb F
does not appear to be regulated by the serum level of Epo.
The Ggamma -158 C→ T mutation is frequent among pa-
tients with beta-thal int, and very rare in patients with tha-
lassemia major, but at variance with sickle cell disease,
increased synthesis of Hb F in beta-thal int patients can-
not be firmly related to the linkage in cis of this muta-
tions.
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